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Background: Nosocomial and ventilator-associated pneumonia (VAP) are causes of significant morbidity and
mortality in hospitalized patients. We analyzed a) the incidence and the outcome of pneumonias caused by
different pathogens in the intensive care unit (ICU) of a medium-sized twenty-four bed community hospital and b)
the incidence of complications of such pneumonias requiring surgical intervention such as thoracotomy and
decortication.
Results: We retrospectively reviewed the charts of patients diagnosed with nosocomial and ventilator-associated
pneumonia in our ICU. Their bronchoalveolar lavage (BAL) and sputum cultures, antibiograms, and other clinical
characteristics, including complications and need for tracheostomy, thoracotomy and decortication were studied. In
a span of one year (2011–12), 43 patients were diagnosed with nosocomial pneumonia in our ICU. The median
simplified acute physiology score (SAPS II) was 39. One or more gram negative organisms as the causative agents
were present in 85% of microbiologic samples. The three most prevalent gram negatives were Stenotrophomonas
maltophilia (34%), Pseudomonas aeurginosa (40%), and Acinetobacter baumannii (32%). Twenty eight percent of
bronchoalveolar samples contained Staphylococcus aureus. Eight three percent of patients required mechanical
ventilation postoperatively and 37% underwent tracheostony. Thirty five percent underwent thoracotomy and
decortication because of further complications such as empyema and non-resolving parapneumonic effusions.
A. baumannii, Klebsiella pneumonia extended spectrum beta lactam (ESBL) and P. aeurginosa had the highest
prevalence of multi drug resistance (MDR). Fifteen patients required surgical intervention. Mortality from pneumonia
was 37% and from surgery was 2%.
Conclusion: Nosocomial pneumonias, in particular the ones that were caused by gram negative drug resistant
organisms and their ensuing complications which required thoracotomy and decortication, were the cause of
significant morbidity in our intensive care unit. Preventative and more intensive and novel infection control
interventions in reducing the incidence of nosocomial pneumonias are strongly emphasized.
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Nosocomial pneumonias, including ventilator-associated,
are the leading cause of infections in a hospital setting.
Their economic burden is financially significant, result-
ing in considerable resource utilization in an era of glo-
bal financial constraint [1]. Mean cost of hospitalization
and treatment could be as high as 100,000 dollars for a
case of VAP. Therefore, prevention of pneumonia in a* Correspondence: docotrbehnia@gmail.com
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reproduction in any medium, provided the orhospital setting is now considered a formidable chal-
lenge. This issue becomes more important when patho-
gen resistance is on the rise and available novel
antimicrobial agents are scarce [1].
Aside from economic constraints, nosocomial pneu-
monias could be potentially fatal because of emergence
of resistance pathogens. Incidence of gram negative or-
ganisms such as P. aureoginosa, S. multophilia, and K.
pneumoniae in addition to methicillin resistant Saphylo-
coccus aureus (MRSA) are on the rise [2,3]. The numbersLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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microbials such as quinolones and carbapenems is escalat-
ing [4,5].
We retrospectively studied the incidence of nosocomial
pneumonia, including VAP, in our hospital intensive care
unit, which is a medium-sized community hospital, for a
period of one year. Clinical characteristics including
length of stay, antibiotic sensitivity and resistance anti-
biograms of the offending organisms were studied in
detail. We further studied complications caused by pneu-
monia requiring surgical interventions of tracheostomy,
thoracotomy, and decortications. Final outcome and
mortality data are also included. We try to convey the
message that thoracotomy and decortication that are his-
torically considered to be interventions of high morbidity
and mortality, could be done safely with low mortality in
an era of multidrug resistant complicated pneumonias by
an experienced team in a medium sized hospital.
Methods
Diagnosis of pneumonia
The following criteria were used when a diagnosis of
pneumonia in ICU was made: radiographic appearance
of a new infiltrate or consolidation, temperature of
greater than 100.5 F, leukocytosis, and increase in tra-
cheobronchial mucus production; other criteria which
may have been present included worsening oxygenation
and positive blood culture [6]. The ICU was a 24-bed,
with an annual admission of 1420 patients.
Microbiology
Microbiologic diagnosis was made by obtaining sample
of tracheobroncial tree by endotracheal suctioning or
by bronchoalveolar lavage through bronchoscopy [6].
Quantitative culture analysis was done in microbiology
laboratory which is as follows: in brief bronchoalveolar
lavage fluid was incubated aerobically at 35 degrees or
under 5% CO2 per published laboratory protocols. The
plates were read for growth after 24 hours of incubation
and the pathogen was worked up accordingly. Another
reincubation was done for 24 hours and plates were read
for growth the following day. Recovery of more than
100,000 colony forming unit (CFU)/ml in a lavage sam-
ple was considered to be positive.
Culture positivity was based on the number of culture
colony-forming units greater than or equal to 104/mm
as the threshold value for a positive culture. Bacterial
identification and antibiotic susceptibility testing with
minimum inhibitory concentration (MIC) panel was per-
formed as per existing laboratory protocols.
Thoracotomy
Open decortication through an anterior approach in-
volving limited thoracotomy was performed by onecardiothoracic surgeon for all the patients requiring
surgery. Decision for surgery was made if there was
presence of a non-resolving, organizing and persistent
pleural effusion which was refractory to conventional
treatments including antimicrobial therapy and chest
tube placement; other criteria for surgery included lack
of improvement in patient’s condition, worsening of oxy-
genation, fever, and leukocytosis. Computerized tomog-
raphy (CT) scan of chest was done in all patients
requiring surgery. We did not use streptokinase or any
fibrinolytic agent through chest tube instillation in any
of our patients prior to surgery.
Other criteria
Other comorbidities were calculated in every patient
using SAPS II score. Patients, who met criteria for end
organ dysfunction and septic shock, received activated
protein C or drotrecogin alfa, per existing protocol at
our institution as follows:
Patient had to meet at least 3 of the following: core
temperature greater than 38C or less than 36C; heart
rate greater than 90 beats/minute, respiratory rate
greater than 20/minute or PaCO2 less than 32 mmHg or
the use of mechanical ventilation for an acute respiratory
process, WBC greater than 12,000/mm3 or less than
4000/mm3 or a differential count with > 10% immature
neutrophils; furthermore patients had to meet at least one
of the following: a) arterial systolic blood pressure < 90
mmHg or mean arterial BP < 70 mmHg for at least 1
hour despite fluid resuscitation or the use of vasopressor
in an attempt to maintain a systolic BP > 90 mmHg, b)
urine output < 0.5 ml/kg for one hour despite adequate
fluid resuscitation, c) PaO2 to FIO2 ratio < 250 in the
presence of other dysfunctional organs/systems or < 200
if the lung was only dysfunctional organ; d) platelet count <
80,000/mm3 or a decrease by 50% in the 3 days prior to
enrollment; e) unexplained acidosis with a pH < 7.3 or the
base deficit of > 5 mmol/L in association with a plasma
lactate level that was > 1.5 times the upper limit of
normal.
Statistical analysis
Data were incorporated into a spreadsheet and subse-
quently imported into the statistical program systat. De-
scriptive statistics were assessed and chi square tests
were used to determine relationships between variables
(e.g., between organism and death). Incidence was assessed
by the number of subjects in a given category relative to
the total population.
Results
Forty three patients met the clinical and microbiologic
criteria for diagnosis of nosocomial pneumonia. Some
had more than one organism on microbiology culture of
Table 2 Mortality and its association with microbiology
of cause of pneumonia
Microbiologic agent
cause of mortality
Number of death (Nosocomial;






Klebsiella (ESBL) (0;1;1)- 2%
Other agents(none of the above) (4;0;4)- 17%
Multidrug Resistance (7;3;10)- 23%
Gram stain Gram positive: (9;1;10)-23%
Gram negative: (9;7;16)-37%
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organisms were positive (Tables 1, 2, 3 and 4). Of the 43
patients with nosocomial pneumonia, 36 were on mech-
anical ventilation. Two had prior tracheostomy. Sixteen
of 43 required tracheostomy during their ICU stay be-
cause of inability to be weaned off the ventilator. Fifteen
of the 43 patients (35%) developed non-resolving com-
plicated parapneumonic effusion with or without empy-
ema and required to undergo thoracotomy and
decortications. All the surgeries were performed by one
cardiothoracic surgeon. Twenty three of the 43 patients
had diagnosis of septic shock requiring vasopressor sup-
port. Summary of findings and other comorbidities are
detailed in Tables 1, 2, 3, 4, and 5. Four patients met cri-
teria for initiation of drotrecogin alfa. Sixteen of the 43
patients died (37%). The incidence of organisms and
their antibiotic sensitivity and resistance are shown in
Figures 1, 2, 3 and 4. Nurse to patient ratio was 1 to 2
for all of the patients.
There were no strong relationships between multi
drug resistant strains and death or surgical intervention,
between VAP and nosocomial pneumonia or between
gram (−) and gram (+). However the association be-
tween MDRS and death had a chi square statistic of 0.13
which was suggestive of a relationship. In addition, there
were borderline relationships between other organisms
and death including Stenotrophomonas/Acinetobacter/or
Both (chi square statistic 0.11), Klebsiella (ESBL) (0.16),
Other agents (none of above) (0.06) and if subjects were
Gram Positive (0.12).
Discussion
Our data provide the following results: a) Gram nega-
tives and MRSA are leading causes of nosocomial and
VAP in our intensive care; b) previously uncommon
gram negatives such as Stenotrophomonas maltophilia
and Acinetobacter baumannii are becoming more preva-
lent; c) a large group of patients further required thora-
cotomy, decortication, and tracheostomy because ofTable 1 Demographic and outcome of patients with
nosocomial and ventilator associated pneumonia
Study population and clinical summary
N 43 patients
Gender (male/female) 18/25
Age (yrs) 65.9 ± 16.8 (range 26-93)
Length of hospital stay (days) 26.7 ± 15.9 (range 5-71)
Average day of hospital stay
patient developed positive
cultures for noscomial pneumonia
9.6 ± 6.4 (range 2-28)
Discharge plan Home: 6 patients
Other Facility: 21 patients
Death: 16 patientsensuing complication; d) thoracotomy and decortication
can be done safely in patients with complicated and non
resolving chest infections and pneumonias with a low
mortality.
Nosocomial pneumonia is a disease with significant
morbidity, mortality, and economic burden. Prevention
plays a considerable role in reducing the incidence of
this disease. Use of VAP prevention bundles appears to
lower its incidence. Despite implementation of strict
preventative bundle (subglottic suctioning, head of the
bed elevation, strict hand washing, use of rotational spe-
cialty beds) the incidence of VAP remains high.
At our institution, a high incidence of gram negative
organisms, in particular uncommon pathogens such as
A. baumannii and S. maltophilia, has been of concern.
Their incidence is surpassing other common gram nega-
tive organisms such as P. aeruginosa, and K. pneumo-
niae. Their high incidence also surpasses MRSA
(Table 4). The trend is of concern and the exact cause
has yet to be clearly established. One previous report
from our institution identified the organisms as the
cause of a pseudo outbreak [7]; the cause was traced
back to a contaminated bronchoscope; however we
doubt that this is the cause for the high number of these
organisms as the cause of pneumonias because of a very
strict infection control policy that has been implemented
since the outbreak occurred. This includes interventionsTable 3 Characteristics of patients with mortality
Characteristics Number of death
(percent of total)
Renal failure requiring dialysis 3 (7%)
Received Drotrecogin alfa 2 (4.6%)




Postoperative Myocardial infarction 3 (9%)
Table 4 Interventions and complications in patients with
nosocomial and ventilator associated pneumonia
Need for mechanical ventilation: 36 patients
Need for tracheostomy during hospitalization: 16 patients
Chronic tracheostomy prior to admission: 2 patients








Septic shock: 23 patients
Required drotrecogin alfa: 4 patients
Average SAPS II score: 39
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care unit and use of disposable and sterile drapes.
One possible reason for the high trend of infections is
because our center is a tertiary referral center for the
outlying smaller medical centers, with a high admission
rate for complex medical problems. The other reason
may be because of our large Burn Center which is the
largest in the Southwest United States, although the sta-
tistics of our burn unit is not included in our study.
Patients affected with pneumonias caused by A. bau-
mannii and MRSA have been shown to be mechanical
ventilator-dependent for a longer time and to cause
more bacteremia [8]. Also SAPS II score was an inde-
pendent variable associated with a higher mortality. In
one study the average SAPS II score was 51.5 for pneu-
monia patients with bacteremia and 46.6 for pneumonia
patients without bacteremia [8]. In the same study, sep-
tic shock was seen in approximately 38% of patients in
both groups and mortality of bacteremic and non-
bacteremic patients were 57% and 33%, respectively.
Interestingly, the same study which was a large multi-
center, multinational, cohort, prospective study showed
that MRSA was the isolated organism causing pneumo-
nia in 14% of patients. In the same study, Pseudomonas
species was the organism isolated in 17%, A. baumannii
in 14%, and S. maltophilia in 2.6% of respiratory tract
isolated cultures (Figure 1).
We did not study the rate of bacteremia caused by
each specific organism; however, previous studies have
shown that A. baumannii and MRSA are independent
predictors of bacteremia after confounders have been
adjusted [8]. The conclusion drawn in another cohort
matched study by Fagon et al. demonstrates that pneu-
monias in ventilated patients with Pseudomonas or Aci-
netobacter species cause considerable mortality as high
as 71% [9]; the subject is controversial and been debatedintensively; there are other studies that have shown that
Acinetobacter-caused VAP is not associated with either
significant mortality or increased length of stay [10].
In a previous study Acinetobacter pneumonia was re-
ported to be about 6% of VAPs; in our study, this organ-
ism was the causative agent in 15% of patients with
nosocomial pneumonia. We do not know why our insti-
tutional numbers were high; previously we reported a
pseudo outbreak caused by a contaminated broncho-
scope [7]; one possible source could be presence of a
large ICU for Burn victims at our institution as the
source of cross contamination. Other likely risk factors
include prior sepsis and antibiotic use, reintubation, dur-
ation of hospital stay and mechanical ventilation, and
the use of imipenem and fluoroquinolone antibiotics
[11].
Pseudomonas pneumonia resistance to imipenem has
been reported in some studies to be around 20 percent
[12].This is very comparable to our present statistics.
The trend may be related to over use of imipenems as a
first line therapy in treatment of Pseudomonas and re-
luctance of clinicians to de-escalate coverage if not
needed [12].
Stenotrophomonas maltophilia, in a prospective obser-
vational case–control study of patients in a 30-bed ICU,
was shown to cause only 2% of pulmonary tract coloni-
zations and infections with this gram negative organism.
Chronic obstructive pulmonary disease (COPD) and
duration of antibiotic treatment were independent risk
factors. Mortality rates, duration of mechanical ventila-
tion and of ICU stay, were significantly elevated in this
infection compared to controls [13]. Our institutional
positive culture rate (20 of 75) was significantly higher
compared to the above study. The exact reason behind
this is unknown but may be related to a higher SAPS II
score of our patients compared to the above study (39
vs. 31). Nevertheless, this discrepancy warrants further
investigation.
Nowadays, MRSA accounts for 20%–40% of all
hospital-acquired and ventilator-associated pneumonias
[14]. All of our institutional strains were vancomycin
and linezolid sensitive. Important factors in prevention
of MRSA pneumonia is strict infection control imple-
mentation and application of VAP bundles. These in-
clude elevation of head of the bed, daily sedation break
and assessment for extubation, peptic ulcer prophylaxis,
use of endotracheal tubes with subglottic suctioning
[15], and oropharyngeal decontamination [15].
An interesting finding of our data was the high num-
ber of patients requiring tracheostomy and thoracotomy
and decortications in our cohort. Thoracotomy was used
mainly in complicated and non resolving parapneumonic
effusions and empyemas as sequels of serious pneumo-
nias. The outcome data of our center with thoracotomy
Table 5 Variables and their assigned severity score used
in calculation of Simplified Acute Physiologic Score II
(SAPS II)
Variable Range Points





> 80 years 18
Type of admission Scheduled surgery 0
Medical 6
Unscheduled surgery 8
Temperature < 39° C, < 102.2° F 0
≥ 39° C, ≥ 102.2° F 3
Systolic blood pressure ≥ 200 mmHg 2
100-199 mmHg 0
70-99 mmHg 5
< 70 mmHg 13




< 40 bpm 11





Urine output ≥ 1 L/24 hours 0
0.5-0.999 L/24 hours 4
< 0.5 L/24 hours 11
White blood cell count < 1000/ mm3 12
1000-19,000/mm3 0
≥ 20,000/mm3 3
Blood urea nitrogen ≥ 30 mmol/L, ≥ 84 mg/dL 10
10-29.9 mmol/L, 28-83 mg/dL 6
< 10 mmol/L, < 28 mg/dL 0
Potassium level < 3 mEq/L 3
3-4.9 mEq/L 0
≥ 5mEq/L 3
Sodium level < 125 mEq/L 5
125-144 mEq/L 0
≥ 145 mEq/L 1
Bicarbonate level < 15 mEq/L 6
15-19 mEq/L 3
≥ 20 mEq/L 0
Table 5 Variables and their assigned severity score used
in calculation of Simplified Acute Physiologic Score II
(SAPS II) (Continued)




≥ 6 mg/dL, ≥ 102.6 micromol/L 9
PaO2/FiO2 (if mechanically
ventilated or receiving CPAP)
< 100 mmHg 11
100-199 mmHg 9
≥ 200 mmHg 6
AIDS Yes 17
No 0
Metastatic carcinoma Yes 9
No 0
Hematologic malignancy Yes 10
No 0
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lung could be a serious and complicated surgery with
high mortality [16]. However, at our center the mortality
following decortication through open thoracotomy or
video-assistance was only 2 percent. This is a remarkably
good statistics. We speculate the good outcome to be re-
lated to intensive and rigorous postoperative care, com-
petency of one dedicated surgeon performing a high
volume of surgeries, and diligent postoperative nursing
care. Our hospital had the highest number of decortica-
tion surgeries in comparison to other hospitals in the
state of Georgia (personal communication).
Thoracotomy and decortication as surgical interven-






Number of Positive Cultures with each 
organism
Figure 1 Bar graph depicting the frequency of microorganisms


























































































































































Sensitive 90 56 36 33 79 71 43 93 21 71 50
Intermediate 0 44 57 33 7 21 14 0 36 7 7
Resistant 10 0 7 33 14 7 43 7 43 21 73
STENOTROPHOMONAS
(20 isolates)
Sensitive 95 10 85 70
Intermediate 0 60 5 25
Resistant 5 30 10 5
ACINETOBACTER
(12 isolates)
Sensitive 17 0 0 25 33 17 17 58 56 8
Intermediate 0 0 0 0 0 0 25 8 33 8




Sensitive 0 0 0 0 0 80 0 0 0 0 0 0 0 0 0 17 0 0 0 0 100 83
Intermediate 0 0 0 33 0 20 0 0 0 0 0 0 0 0 0 50 33 0 0 0 0 17
Resistant 100 100 100 67 100 0 100 100 100 100 100 100 100 100 100 33 67 100 100 100 0 0
Figure 2 Isolated microorganisms of the respiratory tract in patients with nosocomial and ventilator-associated pneumonia and their
in vitro antibiotic sensitivity (total number of isolates=75).
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nounced conclusively as of yet. There is no good ran-
domized blinded controlled study that has compared
this extensive surgery with traditional interventions such
as chest tube placement and other interventions such as
debridement via video-assisted thoracoscopic surgery
(VATS) and open window thoracotomy [17]. The major
confounding factors in studies that have been published
include, but are not limited to, age and degree of
organization of infected/parapneumonic effusion, sever-
ity of illness in the patient (as measured by SAPS II
score), age of patient, and experience of the surgeon
[17]. It appears that in most studies the results are sig-
nificantly different based on the institution and most
studies provide level 2b or lower level recommendations
[17]. The experience and competence of the surgeon,
quality of care by the nursing staff and the intensivist
physician, and patients’ co morbidities are significant fac-
tors in the final outcome. There are also other studies
such as the observational retrospective study by Kho
et al. which showed that debridement alone without de-
cortication in patients with empyema eventually caused
the same re-expansion of pleural cavity space after
evacuation that was not significantly different from em-
pyema decortication [18]. It seems like that there are
more surgeons who refrain from open thoracotomy anddecortications and are instead favoring other interven-
tions such as VATS for management of pleural effusions
complicating pneumonias; VATS is now being favored
by experienced surgeons in academic and also tertiary
referral centers as a procedure with lower 30-day mor-
tality, sepsis and other postoperative complications in
comparison to open thoracotomy and decortications
[19].
Our center has a very robust and exceptional experi-
ence with decortications for complicated parapneumonic
effusions, entrapped lungs, and empyemas as compli-
cations of nosocomial pneumonias. We use a limited
anterior thoracotomy which significantly lowers the
morbidity of surgery with lesser effects on lung mechan-
ics. Our mortality, postoperative septicemia, prolonged
chest tube air leak, and tracheostomy appear to be lower
compared to other published studies, although our out-
comes have not been published officially yet. Our results
appear to be exceptionally remarkable for a medium
sized community hospital since high volume of open de-
cortications appears to be a feature of academic institu-
tions and large tertiary referral medical centers which
have the largest published experience with this type of
surgery. We did not use streptokinase or any other fi-
brinolytic agent in the chest tubes. Our previous unpub-



















































































































































Sensitive 100 67 100 67
Intermediate 0 0 0 0




Sensitive 100 100 0 100 100 100 100 100 100 100 100 100 100 100 100
Intermediate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0




Sensitive 100 0 0 0 50 50 100 50 0 100
Intermediate 0 0 0 0 0 0 0 50 0 0
Resistant 0 100 100 100 50 50 0 0 100 0
PROVIDENCIA STUARTII
(2 isolates)
Sensitive 0 50 0 0 0 100 0 0 100 50 50 100 0 100 100 0 100 100
Intermediate 0 0 0 0 0 0 100 0 0 50 50 0 0 0 0 100 0 0
Resistant 100 50 100 100 100 0 0 100 0 0 0 0 100 0 0 0 0 0
Figure 3 Isolated microorganisms of the respiratory tract in patients with nosocomial and ventilator-associated pneumonia and their








































































































































































Sensitive 0 0 0 0 100 0 0 100 100 100 100 100 0 100 100 100 100
Intermediate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Resistant 100 100 100 100 0 100 100 0 0 0 0 0 100 0 0 0 0
Enterobacter Aerogenes
(1 isolate)
Sensitive 100 100 0 0 100 0 100 100 100 100 100 100 100 100
Intermediate 0 0 100 0 0 0 0 0 0 0 0 0 0 0
Resistant 0 0 0 100 0 100 0 0 0 0 0 0 0 0
Ecoli
(1 isolate)
Sensitive 0 0 0 100 100 0 0 0 0 0 100 0 0 0 100 100
Intermediate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Resistant 100 100 100 0 0 100 100 100 100 100 0 100 100 100 0 0
MRSA
(11 isolates)
Sensitive 100 82 100 100 0 9 18 0 100 100 100
Intermediate 0 0 0 0 0 0 0 0 0 0 0
Resistant 0 18 0 0 100 91 82 100 0 0 0
Figure 4 Isolated microorganisms of the respiratory tract in patients with nosocomial and ventilator-associated pneumonia and their
in vitro antibiotic sensitivity (total number of isolates=75).
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come. Our surgical team prefers limited or extensive
thoracotomy to fibrinolytic therapy.
Sufficient nursing staffing to provide high quality ICU
care is a very crucial factor in reduction of nosocomial
pneumonias which is regrettably often ignored and not
appreciated by other health care providers [15]. In our
ICU, the nurse to patient ratio is established at 1:2 and
for high acuity patients, e.g. around-the-clock dialysis, is
1:1. This practice has had significant impact on quality
of care and therefore a positive impact in reduction of
the incidence of nosocomial pneumonia. This practice in
conjunction with strict infection control measures, e.g.,
hand washing, quarantine of MRSA colonized patients,
wearing of disposable gown and glove in quarantined
rooms, has shown to be very helpful in lowering cross
contamination between patients and therefore reduction
of nosocomial infections.
The limitations of our study were several. It was a
retrospective study. Selection of antibiotics for treatment
of pneumonia was physician-dependent and there was
not a selection protocol that had been present and
therefore each physician might have used a different
choice of antibiotic for treatment of a specific organism.
The same limitation held true for recommending thora-
cotomy and decortication. There was only one surgeon
that performed all the surgeries; however, decision for
consulting the surgeon and requesting surgery was
dependent on the attending intensivist or non-intesivist
physician. Another limitation of our study was that the
study was not done in a “closed” ICU, meaning that
there was not a dedicated intensivist who would assume
full medical care of all the patients. There were other
non-intensivists that assumed patient’s care and the
decision making process, was not similar amongst
physicians.
Conclusion
The 4 most common organisms causing nosocomial and
VA pneumonias at our intensive care unit were Stenotro-
phomonas maltophilia, Pseudomonas aeurginosa, Acineto-
bacter baumannii, and MRSA. A. baumannii, Klebsiella
pneumonia, and P. aeurginosa were the most frequent or-
ganisms that had multi drug resistance. Thoracotomy and
decortication are life saving procedures with very good
outcomes that could be done safely with a very low mor-
bidity and mortality by an experienced surgeon.
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